NZ756707B2 - Antibodies specifically binding to human il-1r7 - Google Patents
Antibodies specifically binding to human il-1r7 Download PDFInfo
- Publication number
- NZ756707B2 NZ756707B2 NZ756707A NZ75670718A NZ756707B2 NZ 756707 B2 NZ756707 B2 NZ 756707B2 NZ 756707 A NZ756707 A NZ 756707A NZ 75670718 A NZ75670718 A NZ 75670718A NZ 756707 B2 NZ756707 B2 NZ 756707B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- region
- antigen
- seq
- previous
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims abstract 11
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 claims 2
- 101001019615 Homo sapiens Interleukin-18 receptor accessory protein Proteins 0.000 claims 2
- 102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000000159 protein binding assay Methods 0.000 claims 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002825 functional assay Methods 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Abstract
The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.
Claims (14)
1. A monoclonal dy, or an antigen-binding fragment thereof, capable of binding to human IL-1R7 comprising six CDR regions of the SEQ ID NOs shown in a single row of the following table CDR1H CDR2H CDR3H CDR1L CDR2L CDR3L 309 457 605 753 901 1205 309 457 605 753 901 1049
2. Antibody or antigen-binding fragment according to claim 1, comprising: a) a VH region comprising a CDR1H region of SEQ ID NO: 309, a CDR2H region of SEQ ID NO: 457 and a CDR3H region of SEQ ID NO: 605 and b) a VL region comprising a CDR1L region of SEQ ID NO: 753, a CDR2L region of SEQ ID NO: 901 and a CDR3L region of SEQ ID NO: 1205.
3. Antibody or antigen-binding fragment according to any one of the previous claims, wherein the antibody comprises a heavy chain variable (VH) region that is at least 90 % identical to the VH region of SEQ ID NO: 1189.
4. Antibody or antigen-binding fragment according to any one of the previous , n the antibody comprises a light chain variable (VL) region that is at least 90 % identical to the VL region of SEQ ID NO: 1203.
5. dy or antigen-binding fragment according to any one of the previous claims, exhibiting an inhibition of IL-18 signaling of at least 30 %, in an IL-18 functional assay. 1005289460
6. Antibody or antigen-binding fragment according to any one of the previous claims, exhibiting a binding specificity to cells sing human IL-1R7 receptor of more than 10.000 RFU in an huIL-1R7 cell binding assay.
7. Antibody or n-binding nt ing to any one of the previous claims, exhibiting a binding specificity to cells sing human IL-1R5 receptor of less than 1.000 RFU in an huIL-1R5 cell binding assay.
8. Antibody or antigen-binding fragment according to any one of the previous claims, wherein the dy is a rabbit, rabbit/human ic or humanized antibody.
9. Antibody or antigen-binding nt ing to any one of the previous claims, exhibiting a reduced affinity to the human Fc? receptors compared to the wildtype IgG Fc?.
10. Antibody or antigen-binding fragment according to any one of the previous claims, wherein signaling through the human Fc? receptor is reduced compared to the wildtype IgG Fc? receptor signaling.
11. Use of the antibody or antigen-binding fragment according to any one of the previous claims in the manufacture of a medicament for the treatment of a IL-18 mediated disease.
12. The use according to claim 11, wherein the disease is an immune disease or an autoimmune disease or an matory or an autoinflammatory disease or a cardiovascular disease.
13. The use according to claim 11 or 12, wherein the disease is selected from the group consisting of type 1 or 2 diabetes, inflammatory bowel disease, Crohn’s disease (CD); ulcerative colitis (UC), multiple sclerosis, sarcoidosis, Giant Cell arthritis (GCA), age-related macular degeneration (AMD), chronic obstructive pulmonary disease (COPD), adult onset Still’s e (AOSD), systemic juvenile idiopathic 1005289460 arthritis (SJIA), severe asthma, Uvenitis, Geographic Atrophy, atherosclerosis and tumor-induced chronic inflammation.
14. A pharmaceutical composition comprising a ceutically acceptable carrier and a eutically effective amount of the antibody or antigen-binding fragment according to any one of claims 1-10. 1005289460 1 I74
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17160191 | 2017-03-09 | ||
| PCT/EP2018/055934 WO2018162724A1 (en) | 2017-03-09 | 2018-03-09 | Antibodies specifically binding to human il-1r7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ756707A NZ756707A (en) | 2024-07-05 |
| NZ756707B2 true NZ756707B2 (en) | 2024-10-08 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3592384T3 (en) | Antibodies specifically binding to human il-1r7 | |
| JP2024150751A5 (en) | ||
| CN113527485B (en) | Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof | |
| JP6513657B2 (en) | IL-17A binding agent and use thereof | |
| CN110669135B (en) | Bispecific antibody and application thereof | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| RU2010149746A (en) | CROSS-REACTIVE ANTIBODIES ANTI-IL-17A / IL-17F AND WAYS OF THEIR APPLICATION | |
| CN114286827B (en) | Humanized anti-IL17A antibodies and their applications | |
| JP2015502145A5 (en) | ||
| JP2012524071A5 (en) | ||
| JP2017510567A5 (en) | ||
| US20200369774A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
| JP2017533888A5 (en) | ||
| KR20220030934A (en) | Anti-GAL9 immuno-suppressive binding molecule | |
| TW202212359A (en) | Antibody that binds to human IL-33, its preparation method and use | |
| JPWO2020254827A5 (en) | ||
| JP2021500913A5 (en) | ||
| NZ756707B2 (en) | Antibodies specifically binding to human il-1r7 | |
| JP2019518473A5 (en) | ||
| JP7689125B2 (en) | Multispecific antibodies with binding specificity for human IL-13 and IL-17 | |
| IL277899B2 (en) | Methods and compositions for treating yellow fever | |
| CN114573703A (en) | Development and application of T cell adaptor therapeutic agent | |
| JPWO2022226342A5 (en) | ||
| JP2020505465A5 (en) | ||
| JP2019507102A (en) | Anti-human IL-3 antibodies, their use in diseases or dysfunctions associated with elevated expression or levels of IL-3, and their use in methods of detecting human IL-3 |